StockData
PMGC Holdings Inc. logo

PMGC Holdings Inc. (ELAB) stock

ELABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/3095% below fair value
$1.48−0.18 (-10.84%)

Close on Nov 17, 2026Market cap $1.32MP/E –Yield –

PMGC r&d expenses

Research and development expenses are spending on new products and technology.

PMGC's R&D Expenses for the twelve months ending Sep 30, 2026 was $520.44K, up 292.8% year over year. For fiscal 2025 it was $147.01K, up 40.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$147.01K+40.5%
FY2024Dec 31, 2024$104.65K+1312.3%
FY2023Dec 31, 2023$7.41K-96.8%
FY2022Dec 31, 2022$228.75K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$130.26K+768.4%
Q2 FY2026Jun 30, 2026$310.22K+365.3%
Q1 FY2026Mar 31, 2026$47.06K+706.9%
Q4 FY2025Dec 31, 2025$32.90K-26.9%
Q3 FY2025Sep 30, 2025$15.00K+266.0%
Q2 FY2025Jun 30, 2025$66.68K+91.5%
Q1 FY2025Mar 31, 2025$5.83K+109.6%
Q4 FY2024Dec 31, 2024$45.00K-63.3%
Q3 FY2024Sep 30, 2024$4.10K-95.3%
Q2 FY2024Jun 30, 2024$34.82K-73.9%
Q1 FY2024Mar 31, 2024$2.78K-96.7%
Q4 FY2023Dec 31, 2023$122.47K-99.9%
Q3 FY2023Sep 30, 2023$86.37K–
Q2 FY2023Jun 30, 2023$133.65K–
Q1 FY2023Mar 31, 2023$83.74K–
Q3 FY2022Sep 30, 2022$89.33M–

More PMGC figures

See a number that looks wrong?